Orexo AB Stock price

Equities

ORX

SE0000736415

Pharmaceuticals

Delayed Nasdaq Stockholm 07:43:37 2024-03-28 am EDT 5-day change 1st Jan Change
15.58 SEK +2.50% Intraday chart for Orexo AB +6.42% +0.78%
Sales 2023 639M 59.74M Sales 2024 * 617M 57.66M Capitalization 524M 48.97M
Net income 2023 -128M -11.97M Net income 2024 * -110M -10.29M EV / Sales 2023 1.27 x
Net Debt 2023 277M 25.94M Net Debt 2024 * 290M 27.12M EV / Sales 2024 * 1.32 x
P/E ratio 2023
-4.14 x
P/E ratio 2024 *
-4.78 x
Employees 116
Yield 2023 *
-
Yield 2024 *
-
Free-Float 78.49%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.89%
1 week+6.83%
Current month-2.25%
1 month+0.26%
3 months-0.64%
6 months-4.87%
Current year+1.16%
More quotes
1 week
14.06
Extreme 14.06
15.64
1 month
14.00
Extreme 14
17.00
Current year
13.32
Extreme 13.32
17.00
1 year
8.44
Extreme 8.44
20.10
3 years
8.44
Extreme 8.44
46.68
5 years
8.44
Extreme 8.44
85.70
10 years
8.44
Extreme 8.44
149.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 11-09-30
Director of Finance/CFO 57 22-08-31
Chief Tech/Sci/R&D Officer - 22-10-25
Members of the board TitleAgeSince
Director/Board Member 68 19-04-10
Chairman 65 20-04-15
Director/Board Member 62 01-12-31
More insiders
Date Price Change Volume
24-03-28 15.58 +2.50% 8 251
24-03-27 15.2 +2.70% 30,106
24-03-26 14.8 +0.54% 9,395
24-03-25 14.72 0.00% 18,201
24-03-22 14.72 +0.55% 9,271

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 05:17 am EDT

More quotes
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
  1. Stock
  2. Equities
  3. Stock Orexo AB - Nasdaq Stockholm